mifepristone has been researched along with Depressive Disorder, Major in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (68.18) | 29.6817 |
| 2010's | 6 (27.27) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Bet, PM; Broeder, C; Linsen, F; Meijer, OC; Penninx, BWJH; Sep, MSC; Verhoeven, JE; Vinkers, CH | 1 |
| Belanoff, J; Block, T; Kalin, N; Kushner, H; Petrides, G; Schatzberg, A | 1 |
| Barbero, JD; Bioque, M; Cobo, J; García-Rizo, C; González-Rodríguez, A; Huerta-Ramos, E; Labad, J; Monreal, JA; Soria, V; Tost, M; Usall, J | 1 |
| Golier, JA; Yehuda, R | 1 |
| Rasgon, NL; Roat-Shumway, S; Schatzberg, AF; Watson, K; Wroolie, TE | 1 |
| Schatzberg, AF | 1 |
| Coleman, VH; Kling, MA; Schulkin, J | 1 |
| Herbert, J | 1 |
| Baulieu, EE; Belanoff, JK; Cassidy, F; DeBattista, C; Rothschild, AJ; Schatzberg, AF; Schold, C | 1 |
| El Sheshai, A; Fawzy, W; Fayek, M; Kingsbury, SJ; Loza, N; Rady, A; Simpson, GM | 1 |
| Flores, BH; Keller, J; Kenna, H; Schatzberg, AF; Solvason, HB | 1 |
| Rothschild, AJ | 1 |
| Hui, X; Wang, MW; Zhou, CH | 1 |
| Young, AH | 1 |
| Alva, G; Belanoff, J; Blasey, C; Carpenter, LL; DeBattista, C; Glass, S; Horne, RL; Khan, A | 1 |
| Howland, RH | 1 |
| Nihalani, ND; Schwartz, TL | 1 |
| de Graaff, M; Dirks, A; Groenink, L; Millan, MJ; Olivier, B; Peeters, BW; Verdouw, PM | 1 |
| Carroll, BJ; Rubin, RT | 1 |
| Benton, T; Douglas, SD; Dubé, B; Evans, DL; Gettes, DR; Lai, JP; Lynch, KG; Metzger, D; Tustin, NB | 1 |
| Elizabeth Dye, C; Gallagher, P; Nicol Ferrier, I; Watson, S; Young, AH | 1 |
| Belanoff, JK; Flores, BH; Kalezhan, M; Schatzberg, AF; Sund, B | 1 |
8 review(s) available for mifepristone and Depressive Disorder, Major
| Article | Year |
|---|---|
Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis.
Topics: Affective Disorders, Psychotic; Bipolar Disorder; Cognition Disorders; Cognitive Dysfunction; Depressive Disorder, Major; Female; Gonadal Steroid Hormones; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Mifepristone; Mood Disorders; Pituitary-Adrenal System; Pregnenolone; Raloxifene Hydrochloride; Schizophrenia | 2018 |
Anna-Monika Award Lecture, DGPPN Kongress, 2013: the role of the hypothalamic-pituitary-adrenal (HPA) axis in the pathogenesis of psychotic major depression.
Topics: Awards and Prizes; Clinical Trials as Topic; Cognition Disorders; Depressive Disorder, Major; Dexamethasone; Dopamine; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Mifepristone; Pituitary-Adrenal System; Psychotic Disorders; Receptors, Corticotropin-Releasing Hormone; Receptors, Glucocorticoid | 2015 |
Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus?
Topics: Adrenal Glands; Aminoglutethimide; Anti-Inflammatory Agents; Corticotropin-Releasing Hormone; Depressive Disorder, Major; Double-Blind Method; Glucocorticoids; Humans; Hydrocortisone; Hypothalamus; Ketoconazole; Metyrapone; Mifepristone; Severity of Illness Index | 2009 |
Cortisol and depression: three questions for psychiatry.
Topics: Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Chronobiology Disorders; Circadian Rhythm; Corticotropin-Releasing Hormone; Dehydroepiandrosterone; Depressive Disorder, Major; Disease Susceptibility; Gene Expression; Gene-Environment Interaction; Hormone Antagonists; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Mifepristone; Neurogenesis; Pituitary-Adrenal System; Psychiatry; Receptors, Glucocorticoid; Risk Factors; Sex Characteristics; Stress, Psychological; Temperament; Treatment Outcome | 2013 |
Glucocorticoid receptor and treatment of psychotic major depression.
Topics: Animals; Brain; Dehydroepiandrosterone; Depressive Disorder, Major; Humans; Metyrapone; Mifepristone; Psychotic Disorders; Pyrimidines; Receptors, Corticotropin-Releasing Hormone; Receptors, Glucocorticoid | 2005 |
Antiglucocoticoid treatments for depression.
Topics: Adrenocortical Hyperfunction; Dehydroepiandrosterone; Depressive Disorder, Major; Enzyme Inhibitors; Hormone Antagonists; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Metyrapone; Mifepristone; Pituitary-Adrenal System | 2006 |
Pharmacotherapy for psychotic depression.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Glucocorticoids; Hormone Antagonists; Humans; Mifepristone; Selective Serotonin Reuptake Inhibitors | 2006 |
Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression.
Topics: Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Glucocorticoids; Hormone Antagonists; Humans; Mifepristone; Molecular Structure; Psychotic Disorders | 2007 |
9 trial(s) available for mifepristone and Depressive Disorder, Major
| Article | Year |
|---|---|
Glucocorticoid Receptor (GR) antagonism as disease-modifying treatment for MDD with childhood trauma: protocol of the RESET-medication randomized controlled trial.
Topics: Adult; Adverse Childhood Experiences; Depressive Disorder, Major; Humans; Hydrocortisone; Mifepristone; Randomized Controlled Trials as Topic; Receptors, Glucocorticoid; Treatment Outcome | 2023 |
Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression.
Topics: Adrenocorticotropic Hormone; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Hydrocortisone; Male; Middle Aged; Mifepristone; Receptors, Glucocorticoid; Treatment Outcome; Young Adult | 2017 |
An open label trial of C-1073 (mifepristone) for psychotic major depression.
Topics: Adult; Aged; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Hormone Antagonists; Humans; Male; Middle Aged; Mifepristone; Psychiatric Status Rating Scales; Treatment Outcome | 2002 |
An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Aged; Depressive Disorder, Major; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Mifepristone; Progesterone; Psychiatric Status Rating Scales; Receptors, Glucocorticoid; Treatment Outcome | 2005 |
Clinical and biological effects of mifepristone treatment for psychotic depression.
Topics: Adrenocorticotropic Hormone; Adult; Depressive Disorder, Major; Double-Blind Method; Female; Hormone Antagonists; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Linear Models; Male; Mifepristone; Psychiatric Status Rating Scales; Receptors, Glucocorticoid; Sex Characteristics | 2006 |
Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression.
Topics: Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Female; Hormone Antagonists; Humans; Male; Middle Aged; Mifepristone; Psychiatric Status Rating Scales; Psychotic Disorders | 2006 |
Selective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus/acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Biphenyl Compounds; Citalopram; Depressive Disorder; Depressive Disorder, Major; Female; Glucocorticoids; HIV Seropositivity; Hormone Antagonists; Humans; Immunity, Innate; Killer Cells, Natural; Lymphocyte Count; Middle Aged; Mifepristone; Personality Inventory; Selective Serotonin Reuptake Inhibitors; Substance P; T-Lymphocytes, Cytotoxic; Viral Load | 2008 |
Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia.
Topics: Bipolar Disorder; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Glucocorticoids; Hormone Antagonists; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Mifepristone; Pituitary-Adrenal System; Placebos; Psychiatric Status Rating Scales; Receptors, Glucocorticoid; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |
Rapid reversal of psychotic depression using mifepristone.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Brief Psychiatric Rating Scale; Cross-Over Studies; Depressive Disorder, Major; Double-Blind Method; Female; Hormone Antagonists; Humans; Hydrocortisone; Male; Middle Aged; Mifepristone; Psychotic Disorders; Time Factors | 2001 |
5 other study(ies) available for mifepristone and Depressive Disorder, Major
| Article | Year |
|---|---|
Mifepristone as a Psychopharmacologic Agent: Consideration of Efficacy, Plasma Levels, and Mechanism of Action.
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Humans; Mifepristone; Psychotic Disorders | 2018 |
Cognitive effects of mifepristone in overweight, euthymic adults with depressive disorders.
Topics: Aged; Attention; Blood Glucose; Cognition; Depressive Disorder, Major; Executive Function; Female; Glucose Tolerance Test; Hormone Antagonists; Humans; Hydrocortisone; Male; Memory; Middle Aged; Mifepristone; Neuropsychological Tests; Overweight; Verbal Learning | 2018 |
Placebo response in psychotic depression.
Topics: Affective Disorders, Psychotic; Brief Psychiatric Rating Scale; Depressive Disorder, Major; Hormone Antagonists; Humans; Mifepristone; Placebo Effect; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Research Design; Severity of Illness Index; Treatment Outcome | 2005 |
CRF1 not glucocorticoid receptors mediate prepulse inhibition deficits in mice overexpressing CRF.
Topics: Acoustic Stimulation; Adrenalectomy; Animals; Benzodioxoles; Depressive Disorder, Major; Disease Models, Animal; Gene Expression; Genotype; Hormone Antagonists; Infusions, Parenteral; Male; Mice; Mice, Transgenic; Mifepristone; Psychotic Disorders; Receptors, Corticotropin-Releasing Hormone; Receptors, Glucocorticoid; Reflex, Startle; Steroids | 2008 |
Mifepristone in psychotic depression?
Topics: Depressive Disorder, Major; Hormone Antagonists; Humans; Mifepristone; Psychotic Disorders | 2008 |